Physician profile
Zhan Yang
NPI 1508205618
$20,629.53
in general payments reported to CMS, 2019-2025
33 companies · $4,363 in 2025
The $4,363 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,641 · 2022: $3,717 · 2023: $5,096 · 2024: $3,813 · 2025: $4,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,170.83 |
| Education | $101.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,996.46 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $2,751.38 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Teva Pharmaceuticals USA, INC. | $2,060.43 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,883.75 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,741.87 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,103.21 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,067.58 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $1,003.01 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $912.76 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Axsome Therapeutics, INC. | $862.62 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $750.51 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $727.08 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $539.98 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $503.73 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $326.86 | 2024-2025 | Cobenfy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $142.28 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $114.96 | 2021-2024 | Contrave, Onzetra Xsail |
| Noven Therapeutics, LLC | $105.52 | 2024-2025 | Secuado, Xelstrym |
| Acadia Pharmaceuticals INC | $100.80 | 2025 | Nuplazid |
| Owp Pharmaceuticals, INC. | $100.08 | 2022-2025 | Subvenite |
| Indivior INC. | $96.69 | 2022-2024 | Perseris |
| Vertical Pharmaceuticals, LLC | $90.46 | 2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $88.36 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $85.88 | 2022-2023 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $80.92 | 2022-2025 | Qelbree, Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $58.75 | 2022 | |
| Novo Nordisk INC | $58.33 | 2023-2025 | Wegovy |
| Pfizer INC. | $56.27 | 2023 | |
| Avanir Pharmaceuticals, INC. | $55.56 | 2021 | |
| Tms Neurohealth Centers INC. | $51.30 | 2025 | Tms Neurohealth Centers INC. |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $48.50 | 2021-2025 | Rexulti |
| Tempus Ai, INC | $46.63 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Brainsway USA INC | $17.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhan Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.